GSK plc Stock

Equities

GSK

GB00BN7SWP63

Pharmaceuticals

Real-time Estimate Cboe Europe 05:15:59 2024-07-08 am EDT 5-day change 1st Jan Change
1,511 GBX +0.02% Intraday chart for GSK plc -0.92% +4.26%
Sales 2024 * 31.61B 40.51B Sales 2025 * 33.62B 43.09B Capitalization 61.62B 78.98B
Net income 2024 * 5.43B 6.95B Net income 2025 * 6.44B 8.26B EV / Sales 2024 * 2.33 x
Net Debt 2024 * 11.95B 15.31B Net Debt 2025 * 8.3B 10.64B EV / Sales 2025 * 2.08 x
P/E ratio 2024 *
11.5 x
P/E ratio 2025 *
9.64 x
Employees 70,212
Yield 2024 *
4.02%
Yield 2025 *
4.17%
Free-Float 94.53%
More Fundamentals * Assessed data
Dynamic Chart

Latest transcript on GSK plc

1 day-0.02%
1 week-0.92%
Current month-1.14%
1 month-6.72%
3 months-6.67%
6 months-2.39%
Current year+4.26%
More quotes
1 week
1 486.00
Extreme 1486
1 535.50
1 month
1 484.00
Extreme 1484
1 640.50
Current year
1 453.20
Extreme 1453.2
1 823.50
1 year
1 302.60
Extreme 1302.6
1 823.50
3 years
1 280.92
Extreme 1280.92
3 408.16
5 years
1 280.92
Extreme 1280.92
3 408.16
10 years
1 280.92
Extreme 1280.92
3 408.16
More quotes
Managers TitleAgeSince
Chief Executive Officer 55 10-04-30
Director of Finance/CFO 62 23-04-30
Compliance Officer - 95-07-31
Members of the board TitleAgeSince
Director of Finance/CFO 62 23-04-30
Chairman 66 19-08-31
Director/Board Member 62 17-12-31
More insiders
Date Price Change Volume
24-07-08 1,511 +0.00% 649 680
24-07-05 1,511 +0.03% 8,159,309
24-07-04 1,510 +0.47% 3,952,157
24-07-03 1,504 0.00% 9,870,467
24-07-02 1,504 -1.47% 7,042,481

Delayed Quote London S.E., July 08, 2024 at 05:00 am EDT

More quotes
GSK plc is a global biopharma company. The Company’s segments include Commercial Operations and Research and Development. It develops cancer medicines for patients, including ovarian cancer, endometrial cancer, and multiple myeloma. Its product areas include vaccines, specialty medicines, and general medicine. It is also focused on addressing the unmet treatment needs of patients with respiratory and inflammatory conditions. Its vaccine portfolio includes over 20 vaccines that help to protect people from a range of diseases and infections, including meningitis, shingles and flu, among others. Its specialty medicines are also engaged in developing medicines for respiratory disease and HIV. Its general medicines include inhaled medicines for asthma and chronic obstructive pulmonary disease, antibiotics, and medicines for skin diseases. It is advancing oligonucleotide therapeutics in chronic hepatitis B and steatotic liver disease as well as other therapeutic areas beyond liver disease.
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
22
Last Close Price
15.11 GBP
Average target price
20.17 GBP
Spread / Average Target
+33.46%
Consensus